Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8064215 | 0.85 | MAPT (0.37) | ALDH1A1TDP1HPGDKDM4EGAA | |
| SCHEMBL15453986 | 0.77 | ALDH1A1 (0.34) | ALDH1A1TDP1HPGDKDM4EGAA | |
| SCHEMBL10987049 | 0.74 | RAPGEF4 (0.31) | ALDH1A1KDM4EGAAMAPTLMNA | |
| SCHEMBL3992773 | 0.74 | ACHE (0.35) | ALDH1A1TDP1HPGDKDM4EHSD17B10 | |
| SCHEMBL6612921 | 0.73 | ALDH1A1 (0.34) | ALDH1A1TDP1HPGDKDM4EGAA | |
| SCHEMBL4429990 | 0.73 | ELANE (0.38) | ALDH1A1TDP1HPGDKDM4EHSD17B10 | |
| SCHEMBL699897 | 0.73 | ALDH1A1 (0.46) | ALDH1A1TDP1HPGDKDM4EGAA | |
| SCHEMBL4553496 | 0.72 | ALDH1A1 (0.39) | ALDH1A1TDP1HPGDKDM4EGAA | |
| SCHEMBL2525468 | 0.72 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL7455159 | 0.72 | RAB9A (0.41) | ALDH1A1HPGDHSD17B10SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952102-B2 | Alkyl ether compositions and methods of use | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2015-02-10 | — | — | US | claimed |
| US-20140288332-A1 | ALKYL ETHER COMPOSITIONS AND METHODS OF USE | CRESTLINE DIRECT FINANCE, L.P. | 2014-09-25 | — | — | US | claimed |
| US-8779070-B2 | Alkyl ether compositions and methods of use | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-07-15 | — | — | US | claimed |
| WO-2014021844-A1 | ALKYL ETHER COMPOSITIONS AND METHODS OF USE | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-02-06 | — | — | WO | claimed |
| US-20140039214-A1 | ALKYL ETHER COMPOSITIONS AND METHODS OF USE | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-02-06 | — | — | US | claimed |
| US-8952102-B2 | Alkyl ether compositions and methods of use | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140288332-A1 | ALKYL ETHER COMPOSITIONS AND METHODS OF USE | CRESTLINE DIRECT FINANCE, L.P. | 2014-09-25 | — | — | US | disclosed |
| US-8779070-B2 | Alkyl ether compositions and methods of use | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-07-15 | — | — | US | disclosed |
| WO-2014021844-A1 | ALKYL ETHER COMPOSITIONS AND METHODS OF USE | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20140039214-A1 | ALKYL ETHER COMPOSITIONS AND METHODS OF USE | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-02-06 | — | — | US | disclosed |
| EP-1373249-B1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTIINFLAMATORY AGENT | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| EP-1373249-A1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTINFLAMATORY AGENT | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002072573-A1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTINFLAMATORY AGENT. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288332-A1 | ALKYL ETHER COMPOSITIONS AND METHODS OF USE | MOGAT2, ARCN1, COPE | ALDH1A1 1821/4885TDP1 2566/4885HPGD 2953/4885 |
| US-20140039214-A1 | ALKYL ETHER COMPOSITIONS AND METHODS OF USE | MOGAT2, ARCN1, COPE | ALDH1A1 1821/4885TDP1 2566/4885HPGD 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.